The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jan. 19, 2021
Filed:
Sep. 21, 2011
Robert M. Jones, San Diego, CA (US);
Juerg Lehmann, San Diego, CA (US);
Weichao Chen, San Diego, CA (US);
Jeffrey Edwards, San Diego, CA (US);
Glen Marquez, San Jose, CA (US);
Michael E. Morgan, San Diego, CA (US);
Abu J. M. Sadeque, San Diego, CA (US);
Sun Hee Kim, San Diego, CA (US);
Robert M. Jones, San Diego, CA (US);
Juerg Lehmann, San Diego, CA (US);
Weichao Chen, San Diego, CA (US);
Jeffrey Edwards, San Diego, CA (US);
Glen Marquez, San Jose, CA (US);
Michael E. Morgan, San Diego, CA (US);
Abu J. M. Sadeque, San Diego, CA (US);
Sun Hee Kim, San Diego, CA (US);
Arena Pharmaceuticals, Inc., San Diego, CA (US);
Abstract
The present invention relates to the GPR119 receptor agonists: 3-fluoro-4-(5-fluoro-6-(4-3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N,N-imethylbenzamide; 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)-N-methylbenzamide; and 3-fluoro-4-(5-fluoro-6-(4-(3-(2-fluoropropan-2-yl)-1,2,4-oxadiazol-5-yl)piperidin-1-yl)pyrimidin-4-ylamino)benzamide, and pharmaceutically acceptable salts, solvates, and hydrates thereof, that are useful as a single pharmaceutical agent or in combination with one or more additional pharmaceutical agents, such as, a DPP-IV inhibitor, a biguanide, an alpha-glucosidase inhibitor, an insulin analogue, a sulfonylurea, an SGLT2 inhibitor, a meglitinide, a thiazolidinedione, or an anti-diabetic peptide analogue, in the treatment of, for example, a disorder selected from: a GPRI19-receptor-related disorder; a condition ameliorated by increasing secretion of an incretin; a condition ameliorated by increasing a blood incretin level; a condition characterized by low bone mass; a neurological disorder; a metabolic-related disorder; type 2 diabetes; obesity; and complications related thereto.